Emerging Strategies and Pathways.
Treatment of Systemic Sclerosis, Scleroderma.
JSRD, Journal of Scleroderma and Related Disorders.
Volume 1 Number 2 May - August 2016.
Emerging Strategies and Pathways.
Treatment of Systemic Sclerosis, Scleroderma.
JSRD, Journal of Scleroderma and Related Disorders.
Volume 1 Number 2 May - August 2016.
Key
pathways in the pathogenesis of SSc and disease-modifying treatment strategies.
The interplay between immune dysfunction, vascular damage, and accumulation of extracellular matrix is indicated by ↔; known or putative mechanism of action(s) of novel therapeutics is indicated by –; and additional pathways which may be disrupted by novel treatments are indicated by – –.
The interplay between immune dysfunction, vascular damage, and accumulation of extracellular matrix is indicated by ↔; known or putative mechanism of action(s) of novel therapeutics is indicated by –; and additional pathways which may be disrupted by novel treatments are indicated by – –.
This infographic appears in the article 'emerging strategies for the treatment
of systemic sclerosis, scleroderma', published in the Journal of Scleroderma
and Related Disorders Volume 1 Number 2 May - August 2016. Click here
To read my synopsis of the article 'emerging strategies for the
treatment of systemic sclerosis, scleroderma' Click here
BSR and BHPR guideline for the prescription and monitoring of
non-biologic disease-modifying anti-rheumatic drugs, Raynaud's, Scleroderma,
Rare Disease, Click here
EULAR guidelines for treatment of systemic sclerosis scleroderma, Click here
May 2017.
To read my articles:
Rare Disease Day 2018, Research - Taking Part in Clinical Trials, Click here
March Autoimmune Disease Awareness Month 2018, Click here
Global patient video, Click here
Becoming a Patient Research Ambassador for the NIHR, Click here
If we only had more RESEARCH investment for Scleroderma, Raynaud's, Autoimmune Rare Disease, Click here
The Importance of Medical Research and Awareness to the Scleroderma, Raynaud's, Autoimmune Rare Disease patient, Click here
The Pandora’s Box of the rare autoimmune disease
Scleroderma, Raynaud's and Cancer, Click here
World Scleroderma Day 29th June 2017, Click here
Why Global Collaboration is important to the Rare Disease Patient, Click here
RARE DISEASE DAY:
Rare Disease Day 2018 – Research, Taking
Part in Clinical Trials. Scleroderma, Raynaud's, Autoimmune Rare Disease, Click here
2016 Rare Disease Day Patient Voice
2016 Rare Disease Day Patient Voice
Rare
Disease Day is a fantastic opportunity for the entire rare disease
community to shine a spotlight on their reality, combining as one unified
voice. Where, at least one commonality presides –
Medical
Research provides the brightest light
for the illumination of the rare disease
patients’ plight.
I
highlighted other areas of medical research interest within Week 3 of my Patient Profiles Campaign for Scleroderma Awareness Month 2017.
VIDEO
VIDEO
Although
rare disease patients are few in number, eg. 2.5 million scleroderma patients
worldwide, (the World Scleroderma Foundation), the commonalities and golden
hallmark for each rare disease patient are the same:
Early Diagnosis
Expert Specialist Centres
Access to Innovative Medicines
Where MEDICAL RESEARCH investment
is VITAL.
Research
is the key. Abstracts from 2016 World Congress, Click here
The Family Day at the Scleroderma Unit, The Royal
Free Hospital is taking place on the 19th May 2018. Browse the
program, here
This year, I am celebrating 20 years of being a
patient at this world leading expert specialist research centre.
 |
| Sept 2017 |
I am eternally grateful to the global scleroderma
trail blazers Dame Prof Black and Prof Chris Denton, whose commitment and
dedication to unlocking the scleroderma enigma, is nothing other than,
superhuman.
I am truly humbled and inspired by their work
ethic. I am wholly appreciative for Prof Denton’s continued medical expertise
and support, especially during my barrister qualifying years, 1997 -
2004.
1st March 2004, I qualified as a self
employed practising barrister. Further to having been told in 1997, by my
diagnosing doctor, that I was looking at a 15month prognosis.
I very much hope to utilise my professional skills
and qualifications along with my patient experience, to help achieve the
#SclerodermaFreeWorld dream, hoping to improve understanding and best practice,
in the meantime.
For latest updates follow:
Facebook Page:
Twitter: @SclerodermaRF @RaynaudsRf
Google Plus: Raynauds Scleroderma Awareness Global Patients
#SclerodermaFreeWorld
#RaynaudsFreeWorld
#ADAM #Scleroderma
#Raynauds
#RareDisease
Living the dream, scleroderma style.
Please DONATE to help
fund medical research at The Scleroderma Unit,The Royal Free Hospital, London.
100% of your monies will be used for medical
research purposes only. No wages or admin costs. Thank You.
#HOPE
Last Update: April 2018
No comments:
Post a Comment